RANK-L and RANK: T cells, bone loss, and mammalian evolution

Annual Review of Immunology

Volumn 20, Issue , 2002, Pages 795-823

  Theill, Lars E ^a   Boyle, William J ^a   Penninger, Josef M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Osteoclast; Osteoimmunology; T cell dendritic cell interaction; TNF TNFR super family molecules

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RANK PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTHRITIS; AUTOIMMUNITY; BONE ATROPHY; BONE DEVELOPMENT; BONE REMODELING; BREAST DEVELOPMENT; CELL COMMUNICATION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELL; EVOLUTION; IMMUNITY; LYMPH NODE; LYMPHOCYTE DIFFERENTIATION; LYMPHOID CELL; LYMPHOID ORGAN; ORGANOGENESIS; OSTEOCLAST; OSTEOPOROSIS; PERIODONTAL DISEASE; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ARTHRITIS; BONE REMODELING; BONE RESORPTION; CARRIER PROTEINS; CELL DIFFERENTIATION; DENDRITIC CELLS; EVOLUTION; FEMALE; GLYCOPROTEINS; HUMANS; MAMMARY GLANDS, ANIMAL; MEMBRANE GLYCOPROTEINS; MODELS, IMMUNOLOGICAL; OSTEOCLASTS; OSTEOPROTEGERIN; PREGNANCY; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES;

EID: 0036218666     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.20.100301.064753     Document Type: Review

References (130)

1. An endotoxin-induced serum factor that causes necrosis of tumors
2. Lymphocyte in vitro cytotoxicity: Specific release of lymphotoxin-like materials from tuberculin-sensitive lymphoid cells
3. Suicide by order: Some open questions about the cell-killing activities of the TNF ligand and receptor families
4. The TNF and TNF receptor super-families: Integrating mammalian biology
5. FADD/MORT1, a signal transducer that can promote cell death or cell growth
6. Initiation of liver growth by tumor necrosis factor: Deficient liver regeneration in mice lacking type I tumor necrosis factor receptor
7. Cartilage destruction and bone erosion in arthritis: The role of tumour necrosis factor alpha
8. Development and maturation of secondary lymphoid tissues
9. CD40 and CD154 in cell-mediated immunity
10. Cell biology of the osteoclast
11. RANKing the importance of measles virus in Paget's disease
12. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
13. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
14. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
15. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
16. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
17. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
18. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines
19. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice
20. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
21. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
22. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
23. RANK is essential for osteoclast and lymph node development
24. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
25. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
26. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase
27. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily
28. Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB
29. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor
30. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis
31. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
32. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice
33. Requirement for NF-kappa B in osteoclast and B-cell development
34. Osteopetrosis in mice lacking NF-kappa B1 and NF-kappa B2
35. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src
36. A positive regulatory role for Cb1 family proteins in TRANCE and CD40L-mediated Akt activation
37. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL)
38. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
39. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
40. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
41. Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis
42. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells
43. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells
44. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is upregulated by ligating CD40
45. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis
46. Arterial calcification in face of osteoporosis in ageing: Can we blame oxidized lipids?
47. Bone mineral density in acute stroke patients: Low bone mineral density may predict first stroke in women
48. Epidemiology of osteoporosis
49. Reduction of atherosclerosis in mice by inhibition of CD40 signalling
50. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts
51. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
52. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways
53. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
54. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
55. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha
56. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells In vivo
57. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
58. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
59. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin
60. Selective disruption of lymphotoxin ligands reveals a novel set of mucosal lymph nodes and unique effects on lymph node cellular organization
61. Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice
62. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice
63. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers
64. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues
65. Lymph node genesis is induced by signaling through the lymphotoxin beta receptor
66. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2
67. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor
68. Developing lymph nodes collect CD4+CD3-LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells
69. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE
70. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells
71. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells
72. The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation
73. Mice deficient for the CD40 ligand
74. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation
75. Dendritic cells and the control of immunity
76. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells
77. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II
78. Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
79. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity
80. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles
81. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
82. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development
83. Structure and function of the pre-T cell receptor
84. Proapoptotic Bcl-2 relative bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity
85. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function
86. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: Implications for accelerated osteoclastogenesis in estrogen deficiency
87. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene
88. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids
89. Role of cytokines in rheumatoid arthritis
90. Animal models of arthritis: Relevance to human disease
91. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis
92. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor
93. A revival of the B cell paradigm for rheumatoid arthritis pathogenesis?
94. Organ-specific disease provoked by systemic autoimmunity
95. TRANCE/RANKL knockout mice are protected from bone erosion in the K/BxN serum transfer model of arthritis
96. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
97. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
98. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3
99. New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs
100. One-year inhibition of tumor necrosis factor-alpha: A major success or a larger puzzle?
101. Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child
102. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy
103. Bone mineral density and bone metabolism in diabetes mellitus
104. Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus
105. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids
106. How can we improve the treatment of bone metastases further?
107. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection
108. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone
109. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis
110. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone
111. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
112. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
113. Bone versus immune system
114. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma
115. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro
116. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB
117. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1
118. The genetic transformation of bone biology
119. Regulation of mammary gland development by tissue interaction
120. Side-branching in the mammary gland: The progesterone-Wnt connection
121. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation
122. Nutritional deficiencies in the neonate
123. Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: A longitudinal study
124. Colony stimulating factor 1 is required for mammary gland development during pregnancy
125. Prolactin controls mammary gland development via direct and indirect mechanisms
126. Impaired mammary gland development in Cyl-1(-/-) mice during pregnancy and lactation is epithelial cell autonomous
127. The effects of pregnancy on autoimmune diseases
128. A gender gap in autoimmunity
129. Gender and risk of autoimmune diseases: Possible role of estrogenic compounds
130. Gender differences in autoimmunity: Molecular basis for estrogen effects in systemic lupus erythematosus